Ocular Therapeutix, Inc.
OCULHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ocular Therapeutix, Inc. focuses on Biotechnology services and products. Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable. Valued at $2.34B, OCUL is a mid-cap name in its sector. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Market Cap
$2.34B
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-7.32
EPS (TTM)
$-1.40
EPS (Fwd)
$-1.45
ROE
-73.0%
ROA
-34.9%
Cash
$598.6M
Total Debt
$79.4M
Free CF
-$159.2M
52W Change
-16.6%
Annual Financials
Cash vs Debt
Where OCUL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OCUL finished 18.48% above its 150-day moving average ($9.20) and 9.44% above its 200-day moving average ($9.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OCUL overbought or oversold?
At the September 3, 2026 close, OCUL's RSI(14) was 60.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ocular Therapeutix, Inc. holds $598.6M in cash against $79.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$159.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -73.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $51.5M (2022) to $52.0M (2025).
With cash comfortably exceeding debt, OCUL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OCUL.